Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX) announced today that they have entered into a definitive agreement for Lilly to acquire Ventyx, a clinical-stage biopharmaceutical company specializing in oral therapies for inflammatory-mediated diseases.
The acquisition, valued at approximately $1.2 billion, marks Lilly’s first major move in the M&A space for 2026 and underscores the pharmaceutical giant’s strategic commitment to expanding its immunology portfolio beyond its market-leading positions in diabetes and obesity.
The Deal Terms
Under the terms of the agreement, Lilly will acquire all outstanding shares of Ventyx for $14.00 per share in an all-cash transaction. This purchase price represents a premium of approximately 62% over the 30-day volume-weighted average trading price of Ventyx’s common stock as of January 5, 2026. The boards of directors for both companies have approved the transaction, which is expected to close in the first half of 2026, subject to customary closing conditions and regulatory approvals.
Strengthening the Oral Inflammation Pipeline
Ventyx Biosciences has built a robust pipeline of small-molecule therapeutics designed to address the underlying drivers of chronic inflammation. The acquisition brings several high-potential assets into the Lilly Research Laboratories ecosystem:
- VTX3232: A central nervous system (CNS)-penetrant NLRP3 inhibitor. It recently completed Phase 2 trials in patients with obesity and cardiovascular risk factors, as well as a separate biomarker study in early-stage Parkinson’s disease.
- VTX2735: A peripherally restricted NLRP3 inhibitor currently in Phase 2 development for the treatment of recurrent pericarditis.
- Tamuzimod (VTX002): An oral S1P1 receptor modulator in Phase 2 development for inflammatory bowel disease (IBD).
- VTX958: A Phase 2 TYK2 inhibitor targeting various autoimmune conditions.
Strategic Rationale
The acquisition follows a period of intense growth for Lilly, fueled by the success of its GLP-1 medicines. By acquiring Ventyx, Lilly is diversifying its R&D focus toward “residual inflammation,” the inflammatory processes that persist even after metabolic factors are managed. This is particularly relevant in cardiovascular disease and neurodegenerative disorders like Parkinson’s, where NLRP3 inhibition is seen as a promising frontier.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Industry Context
This deal comes just 24 hours after Lilly announced a $1.3 billion research collaboration with Nimbus Therapeutics focused on oral obesity treatments, signaling a highly active start to the year for the Indianapolis-based firm. Analysts suggest that Lilly is utilizing its significant cash reserves to secure “next-generation” oral therapies that offer better safety and convenience than current injectable biologics.
Advisors
BofA Securities, Inc. is serving as the exclusive financial advisor to Lilly, with Ropes & Gray LLP acting as legal counsel. Wilson Sonsini Goodrich & Rosati is serving as legal counsel to Ventyx Biosciences.
Last Modified:
